PSI/ 1500 x 50mL bags of Pentastarch solutions.
Closed Pre-Solicitation Posted
- Solicitation number
- 19-009350
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
Notice text
INTRODUCTION
THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).
The National Institutes of Health (NIH), Clinical Center (CC), Office of Purchasing and Contracts (OPC) on behalf of the Department of Transfusion Medicine (DTM), Clinical Center (CC) at the National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (including brand-name) to:
Preservation Solutions Inc.
1099 Proctor Dr
Elkhorn, WI, 53121-2027
NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE
The intended procurement is classified under NAICS code 325413 with a Size Standard 1250.
REGULATORY AUTHORITY
The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2005-100, August 22, 2018. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold.
STATUTORY AUTHORITY
This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.501 (a), Soliciting from a single source and is expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
GENERAL INFORMATION
1. Title: PSI/ 1500 x 50mL bags of Pentastarch solutions.
2. Background Information The Center Of Cellular Engineering (CCE), Department of Transfusion Medicine, NIH CC is an AABB accredited cellular therapy laboratory whose central mission is to provide services to the NIH Institutes to support more than 50 intramural clinical trials. These services include (1) development, evaluation, and validation of investigational new drugs (INDs) for cellular therapies and (2) manufacture of cellular therapy products for approved clinical trials. The majority of these trials are early phase (I/II) trials not intended to result in the development of a commercial product. To provide these services, CCE operates a core facility (Charles S. Carter Cellular Therapy Laboratory) for the manufacture, storage, and distribution of cellular therapy products. CCE manufactures cellular therapy products from more than 800 collections from patients or healthy donors per year. The products manufactured by the laboratory are used to treat NIH CC patients with cancer, hematological malignancies, marrow failure, genetic immune disorders and autoimmune diseases. All products are manufactured using good manufacturing practices (GMP). The NIH protocols are institutional review board (IRB) approved and in the case of INDs approval by the US Food and Drug Administration (FDA) for treatment of human subjects. Each subject must consent to participate in a NIH Clinical Research Study.
3. Purpose or Objective: To purchase estimated 1500 bags per year of PSI Pentastarch Solution- 50mL bags. Pentastarch is a validated reagent use to make freeze mix. Freeze mix is a necessary component in the cryopreservation of many clinical therapies for fresh infusion and further manufacturing processes.
4. Delivery: Base year plus four option years an approximately start date on or around 7/1/19.
CONTRACTOR REQUIREMENTS (SCOPE OF WORK)
1. The contractor will supply 25 cases/boxes (5 per case or box) of PSI Pentastarch Solution- 50mL bags per month during the performance period.
2. Shelf Life-Minimum - shelf life is required to be six months from the date of receipt unless Cell Processing previously agrees to another arrangement.
3. The reagents and disposables may include but not limited to those listed below:
- PSI Pentastarch Solution- 50mL bags
4. The Contractor shall supply technical support for all supplies and their performance characteristics at no additional cost to the Government.
5.
Period of Performance
The period of performance for the base plus one year option:
07/01/2019 - 06/33/2020 base year
07/01/2020 - 06/30/2021 1st option year
07/01/2021 - 06/30/2022 2nd option year
07/01/2022 - 06/30/2023 3rd option year
07/01/2023 - 06/30/2024 4th option year
Delivery Schedule:
The Company shall deliver the supplies on a standing order, on a monthly basis. Each month the company shall ship 25cases/boxes (5 per case or box) of PSI Pentastarch Solution- 50mL bags without any notification from the Cell Processing Section. Delivery service will include inside delivery to the Cell Processing Section.These medical supplies/equipment will be shipped delivery Monday through Thursday 8:00 AM to 4:00PM to:
NIH/CC/DTM/Center Cellular Engineering
10 Center Drive
Bldg. 10/ Rm. 3C720
Bethesda, MD 20892-1288
Attention: Timmy Ton/Thai Truong
The contractor shall bear the cost of replacement for reagents found to be damaged or defective upon receipt by NIH or for incorrect or incomplete shipments.
Government Responsibilities
1. The Center Cellular Engineering shall use the reagents in accordance with manufacturer's package inserts and approved IND/IDE uses if applicable.
2. The NIH CC Center Cellular Engineering shall inspect shipments upon receipt and report any damage, defects or errors in shipment to the contractor.
CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION
This system is on site and has been validated for use on CC patients. It would be detrimental to the government to attempt to change systems and quite impossible as these instruments are proprietary and only distributed by Veterans Healthcare Supply Solutions. With the continuation of using the same system will also help reduces the risk of a disruption in patient care. The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted as prescribed in FAR Part 10-Market Research.
CLOSING STATEMENT
This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.
All responses must be received by June 3rd, 2019, 1:00 PM Eastern time and must reference solicitation number 19-009350. Responses may be submitted electronically to Mrs. Grace Wong-Darko, Contracting Specialist at Grace.Wong-Darko@nih.gov. Fax responses will not be accepted.
"All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency."
.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity